bioRxivMicrobiologyPreprint
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
D. Planas, I. Staropoli, V. Michel, F. Lemoine, F. Donati, M. Prot, F. Porrot, F. G. Benhassine, B. Jeyarajah, A. Brisebarre, O. Dehan, L. Avon, W. Bolland, M. Hubert, J. Buchreiser, T. Vanhoucke, P. Rosenbaum, D. Veyer, H. Pere, B. Lina, S. T. Assant, L. Hocqueloux, T. Prazuck, E. S. Loriere, O. Schwartz
Abstract
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral sublineages. Here, we isolated and characterized XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 and JN.1 variants, representing >80% of circulating variants in January 2024. The XBB subvariants carry few but recurrent mutations in the spike, whereas BA.2.86.1 and JN.1 harbor >30 additional changes. These variants replicated in IGROV-1 but no longer in Vero E6 and were not markedly fusogenic. They potently infected nasal epithelial cells, with EG.5.1.3 exhibiting the highest fitness. Antivirals remained active. Neutralizing antibody (NAb) responses from vaccinees and BA.1/BA.2-infected individuals were markedly lower compared to BA.1, without major differences between variants. An XBB breakthrough infection enhanced NAb responses against both XBB and BA.2.86 variants. JN.1 displayed lower affinity to ACE2 and higher immune evasion properties compared to BA.2.86.1. Thus, while distinct, the evolutionary trajectory of these variants combines increased fitness and antibody evasion.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Q. Wang, S. Iketani, … D. D. Ho·bioRxiv·Nov 23, 2022
- SARS-CoV-2 Omicron BA.2.86: less neutralization evasion compared to XBB sub-variants
- Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
- Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1
Fanchong Jian, Jing Wang, … Yunlong Cao·NaturePeer-reviewed·Nov 7, 2024
- Antibody Neutralization of Emerging SARS-CoV-2: EG.5.1 and XBC.1.6
- Transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant